Identification of regulatory variants of carboxylesterase 1 (CES1): A proof ‐of‐concept study for the application of the Allele‐Specific Protein Expression (ASPE) assay in identifying cis‐acting regulatory genetic polymorphisms
This study suggests that the ASPE approach is a powerful tool for identifyingcis-regulatory variants.This article is protected by copyright. All rights reserved (Source: Proteomics)
Source: Proteomics - November 22, 2022 Category: Biochemistry Authors: Lucy Her, Jian Shi, Xinwen Wang, Bing He, Logan Smith, Hui Jiang, Hao ‐Jie Zhu Tags: Research Article Source Type: research

Estimating the Time to Benefit for Therapies in Heart Failure with Reduced Ejection Fraction: A Case Study of Sacubitril-Valsartan Using Reconstructed Data from a Randomized Controlled Trial
ConclusionUsing multiple approaches, the earliest benefit of sacubitril-valsartan compared to enalapril in stable HFrEF was found at about 1 month after initiation. (Source: Drugs and Aging)
Source: Drugs and Aging - November 21, 2022 Category: Geriatrics Source Type: research

Effects of Ziyin Qianyang Formula on Renal Fibrosis through the TGF- < em > β < /em > 1/Smads Signaling Pathway in Spontaneously Hypertensive Rats
CONCLUSION: ZYQYF can significantly reduce SHR blood pressure, protect renal function and structure, and improve renal fibrosis by regulating Smad proteins through TGF-β1.PMID:36387359 | PMC:PMC9663231 | DOI:10.1155/2022/6088673 (Source: Evidence-based Complementary and Alternative Medicine)
Source: Evidence-based Complementary and Alternative Medicine - November 17, 2022 Category: Complementary Medicine Authors: Hui Xu Chao Wang Ting-Ting Song Yang Liu Chang-Wu Dong Source Type: research

Comprehensive analyses of the microRNA –messenger RNA–transcription factor regulatory network in mouse and human renal fibrosis
Conclusion: Pax2, Pax5, Sp1, Sp2, Sp3, and Sp4 together with Bckdha-dependent miR-125a-3p/Vegfa-dependent miR-199a-5p formed a co-regulatory network enabling Bckdha/Vegfa to be tightly controlled in the underlying pathogenesis of RF across mice and humans. Vegfa could act as a potential novel diagnostic marker and might be targeted by enalapril for RF therapy. (Source: Frontiers in Genetics)
Source: Frontiers in Genetics - November 15, 2022 Category: Genetics & Stem Cells Source Type: research

Triosephosphate-Isomerase Deficiency: Epiphenomenon or Cause of Loin Pain Haematuria Syndrome?
A 32-year-old male patient presented the clinical picture of loin pain haematuria syndrome with pain attacks accompanied by macrohaematuria. In renal biopsy, the preglomerular vessels showed segmental wall hyalinosis in the sense of low-grade nephrosclerosis, and glomerular capillaries with slightly but diffusely thickened, non-split basal membranes on electron microscopy. Notable were irregularly deformed, different dense erythrocytes in the glomerular capillaries, and several tubular lumina. The suspicion of erythrocytic enzyme deficiency could be confirmed. The enzyme activities of the erythrocytes were predominantly no...
Source: Case Reports in Nephrology and Dialysis - November 11, 2022 Category: Urology & Nephrology Source Type: research

IJERPH, Vol. 19, Pages 14375: The Correlation between Two Angiotensin-Converting Enzyme Inhibitor & rsquo;s Concentrations and Cognition
IJERPH, Vol. 19, Pages 14375: The Correlation between Two Angiotensin-Converting Enzyme Inhibitor&rsquo;s Concentrations and Cognition International Journal of Environmental Research and Public Health doi: 10.3390/ijerph192114375 Authors: Attila Nagy Réka Májer Enikő Csikai Adrienn Dobos Gábor Süvegh László Csiba Both lisinopril and enalapril are angiotensin-converting enzyme (ACE) drugs and widely used in the treatment of hypertension. Enalapril does not cross the blood&amp;ndash;brain barrier, but lisinopril is centrally active. Our goal was to find out if there was a link between the act...
Source: International Journal of Environmental Research and Public Health - November 3, 2022 Category: Environmental Health Authors: Attila Nagy R éka Májer Enik ő Csikai Adrienn Dobos G ábor Süvegh L ászló Csiba Tags: Article Source Type: research

Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril
CONCLUSIONS: Lercanidipine may be regarded as an ideal antihypertensive drug for patients at renal risk and possibly the preferred choice among calcium channel blocker drugs.PMID:36314318 | DOI:10.26355/eurrev_202210_30018 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - October 31, 2022 Category: Drugs & Pharmacology Authors: N Ferri A Corsini R Pontremoli Source Type: research

Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril
CONCLUSIONS: Lercanidipine may be regarded as an ideal antihypertensive drug for patients at renal risk and possibly the preferred choice among calcium channel blocker drugs.PMID:36314318 | DOI:10.26355/eurrev_202210_30018 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - October 31, 2022 Category: Drugs & Pharmacology Authors: N Ferri A Corsini R Pontremoli Source Type: research

Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril
CONCLUSIONS: Lercanidipine may be regarded as an ideal antihypertensive drug for patients at renal risk and possibly the preferred choice among calcium channel blocker drugs.PMID:36314318 | DOI:10.26355/eurrev_202210_30018 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - October 31, 2022 Category: Drugs & Pharmacology Authors: N Ferri A Corsini R Pontremoli Source Type: research

Antihypertensive treatment with calcium channel blockers and renal protection: focus on lercanidipine and lercanidipine/enalapril
CONCLUSIONS: Lercanidipine may be regarded as an ideal antihypertensive drug for patients at renal risk and possibly the preferred choice among calcium channel blocker drugs.PMID:36314318 | DOI:10.26355/eurrev_202210_30018 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - October 31, 2022 Category: Drugs & Pharmacology Authors: N Ferri A Corsini R Pontremoli Source Type: research